FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL					
OMB Number:	3235-0287					
Estimated average burden						
hours per response	0.5					

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	e Responses)																
1. Name and Address of Reporting Person * MALLIK AMEET				2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner							
(Last) (First) (Middle) C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900				3. Date of Earliest Transaction (Month/Day/Year) 06/23/2022								Officer (give	title below)	Oth	er (specify belo	ow)		
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							_X_ F	6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person						
SOUTH SAN FRANCISCO, CA 94080														Form filed by More than One Reporting Person				
(City	7)	(State)	(Zip)			Т	able I	- No	n-Der	ivative S	ecuritie	s Acqu	uired, l	Disposed	of, or Bene	ficially Own	ed	
(Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		ate, if	(Instr. 8)		(4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		d	Ownership Form:	7. Nature of Indirect Beneficial Ownership		
				(Woltan)	Day	(Tear)	Cod	e	V	Amount	(A) or (D)	Price		1. 3 and 4)	14)		or Indirect (I) (Instr. 4)	
Common	Stock		06/23/2022				A			20,500	A	\$ 0	20,500			D		
			Table II -					d .iired	lisplay	ys a cur	rently v	valid (OMB o	control n	unless the umber.	form		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code	tion	5. Num	vative ies ed (A)	6. D Exp (Mo	orth/Day/Year) of Unitration Date of Unitration Date		tr. 3 and 4) (Instr. 5) Be Ov Fo Re Tr			Owners Form of Derivat Security Direct (or Indir	Ownershi (Instr. 4)			
				Code	V	(A)	(D)	Date Exe	e rcisab	Expira Date	ıtion	Title		Amount or Number of Shares		(Instr. 4)	(Instr. 4)
Non- Qualified Stock Option (Right to Buy)	\$ 7.35	06/23/2022		A		31,50	0		(2)	06/22	2/2032		nmon ock	31,500	\$ 0	31,500	D	

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
MALLIK AMEET C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD., SUITE 900 SOUTH SAN FRANCISCO, CA 94080	X					

Signatures

/s/ David Tucker, Attorney-in-Fact for Ameet Mallik	06/27/2022		
**Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These restricted stock units shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
- (2) The option shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.